Adenosine monophosphate-activated protein kinase (AMPK) is a heterotrimeric complex (αβγ) that serves as a master regulator of cellular metabolism, making it a prominent drug target for various diseases. Post-translational modifications (PTMs) and ligand binding significantly affect the activity and function of AMPK. However, the dynamic interplay of PTMs, noncovalent interactions, and higher-order structures of the kinase complex remains poorly understood. Herein, we report for the first time the structural heterogeneity of the AMPK complex arising from ligand binding and proteoforms─protein products derived from PTMs, alternative splicing, and genetic variants─using integrated native and denatured top-down mass spectrometry (TDMS). The fully intact AMPK heterotrimeric complex exhibits heterogeneity due to phosphorylation and multiple adenosine monophosphate (AMP) binding states. Native TDMS delineates the subunit composition, AMP binding stoichiometry, and higher-order structure of AMPK complex, while denatured TDMS comprehensively characterizes the proteoforms and localizes the phosphorylation site. Notably, by integrating native TDMS and AlphaFold, we elucidate a flexibly connected regulatory region of AMPK β subunit that was previously unresolvable with traditional structural biology tools. Our findings offer new perspectives on protein kinase regulation and establish a versatile framework for comprehensive characterization of proteoform-ligand complexes.
T‐cell acute lymphoblastic leukemia (T‐ALL) is a highly aggressive hematologic malignancy with limited targeted therapies. CD28, a costimulatory receptor aberrantly overexpressed on T‐ALL cells, presents a promising underexplored therapeutic target. In this study, we developed an enzyme‐responsive self‐assembling peptide, SA p ‐CD28, designed to target CD28 and undergo receptor‐mediated self‐assembly in the tumor microenvironment. Upon dephosphorylation by overexpressed phosphatases, SA p ‐CD28 transitions from an α‐helix to a β‐sheet/β‐turn rich structure, facilitating the formation of nanooligomers that engage CD28 and activate cytotoxic pathways. Transcriptomic and biochemical analyses reveal that SA p ‐CD28 induces a profound dysregulation of CD28 downstream signaling, characterized by the suppression of the PLCγ and Akt pathways. These signaling perturbations lead to oxidative stress and disruption of intracellular calcium homeostasis, resulting in calcium overload, calpain activation, and cytoskeletal collapse. Besides, confocal imaging suggested that the peptide self‐assembly can enter the nucleus and disrupt it. In Jurkat xenograft models, SA p ‐CD28 demonstrated potent antitumor activity, and its combination with cytarabine resulted in near‐complete tumor suppression, highlighting its potential for T‐ALL treatment. This work introduces a CD28‐targeted, enzyme‐activated nanotherapeutic strategy that synergizes biochemical and mechanical mechanisms to selectively eliminate T‐ALL cells. This multi‐mechanistic tumor‐killing strategy can also be extended to inspire therapeutic approaches for other diseases.
Protein kinases integrate cellular signals through complex phosphorylation cascades, yet resolving how chemical perturbations trigger and modulate these cascades in therapeutic targets remains a major challenge. Here, we dissect adenosine 5′-monophosphate–activated protein kinase (AMPK) proteoforms during activation through controlled biochemical reactions with a hybrid mass spectrometry (MS) approach integrating bottom-up MS for site-specific kinetics with top-down proteoform characterization. We reveal that AMPK phosphorylation proceeds through hierarchical cascades rather than binary switching, with dual entry points: canonical calcium- and calmodulin-dependent protein kinase kinase 2 (CaMKK2)–mediated phosphorylation or allosteric activator PF-739 both triggering extensive autophosphorylation with α1-Ser496 (S496) showing the highest kinetic priority. Proteoform-resolved analysis uncovers channeled β1-Ser24/25 (S24/25) + Ser108 (S108) cophosphorylation linking subcellular localization with allosteric responsiveness. Site-directed mutagenesis demonstrates CaMKK2 targets only α1-Thr183 (T183), with all other modifications arising through autophosphorylation. Phosphatase competition reveals asymmetric control where PP1A selectively removes activation-loop phosphorylation while autophosphorylation sites remain protected, establishing persistent regulatory states. Resolving AMPK’s temporal kinetics and proteoform architecture during activation enables a proteoform-centric understanding on kinase regulation.
Protein kinases integrate cellular signals through complex phosphorylation cascades, yet resolving how chemical perturbations trigger and modulate these cascades in therapeutic targets remains a major challenge. Here, we dissect AMP-activated protein kinase (AMPK) proteoforms during activation through controlled biochemical reactions with a hybrid mass spectrometry (MS) approach integrating bottom-up MS for site-specific kinetics with top-down proteoform characterization. We reveal that AMPK phosphorylation proceeds through hierarchical cascades rather than binary switching, with dual entry points: canonical CaMKK2-mediated phosphorylation or allosteric activator PF-739 both triggering extensive autophosphorylation with α1-S496 showing highest kinetic priority. Proteoform-resolved analysis uncovers channeled β1-S24/25+S108 co-phosphorylation linking subcellular localization with allosteric responsiveness. Site-directed mutagenesis demonstrates CaMKK2 targets only α1-T183, with all other modifications arising through autophosphorylation. Phosphatase competition reveals asymmetric control where PP1A selectively removes activation-loop phosphorylation while autophosphorylation sites remain protected, establishing persistent regulatory states. Resolving AMPK’s temporal kinetics and proteoform architecture during activation enables a proteoform-centric understanding on kinase regulation.
Small extracellular vesicles (sEVs) in human serum carry diverse biomarkers and hold great potential for diagnostic and therapeutic applications. However, their isolation is challenging due to the presence of highly abundant serum proteins, particularly lipoproteins that closely resemble the sEVs in size and density. Existing lipoprotein removal methods cannot effectively remove all types of lipoproteins and may lead to potential contamination. Herein, we developed a lipoprotein‐depleting biomimetic core–shell liposome nanoparticle system composed of Fe 3 O 4 @SiO 2 cores coated with liposome bilayers (SL‐NPs). These lipoprotein‐mimicking nanoparticles exhibit efficient binding to lipoproteins that enable the selective removal of lipoproteins by low‐speed centrifugation while preserving sEVs. When applied as a complementary treatment step, this NP depletion strategy further enhances the purity of sEVs isolated from human serum or human plasma using ultracentrifugation or chemical precipitation methods. Nanoparticle tracking analysis, Western blot, ELISA, and proteomics analysis confirm the depletion of multiple classes of lipoproteins and the improvement of sEV purity after this additional nanoparticle depletion step. This strategy offers a simple, rapid, and effective approach to improve downstream biomarker analysis and applications of blood sEVs.